Humoral autoimmunity against endothelium: Theory or reality?

Research output: Contribution to journalArticle

Abstract

Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalTrends in Immunology
Volume26
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Autoimmunity
Endothelium
Phospholipids
Glycoproteins
Antiphospholipid Syndrome
Autoantibodies
Anti-Idiotypic Antibodies
Carrier Proteins
Endothelial Cells
Antibodies
anti-endothelial cell antibody
In Vitro Techniques
Clinical Studies

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Humoral autoimmunity against endothelium : Theory or reality? / Meroni, Pierluigi; Ronda, Nicoletta; Raschi, Elena; Borghi, Maria O.

In: Trends in Immunology, Vol. 26, No. 5, 05.2005, p. 275-281.

Research output: Contribution to journalArticle

@article{8f6142005f544b8ab932e7a48b90e6eb,
title = "Humoral autoimmunity against endothelium: Theory or reality?",
abstract = "Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.",
author = "Pierluigi Meroni and Nicoletta Ronda and Elena Raschi and Borghi, {Maria O.}",
year = "2005",
month = "5",
doi = "10.1016/j.it.2005.03.006",
language = "English",
volume = "26",
pages = "275--281",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Humoral autoimmunity against endothelium

T2 - Theory or reality?

AU - Meroni, Pierluigi

AU - Ronda, Nicoletta

AU - Raschi, Elena

AU - Borghi, Maria O.

PY - 2005/5

Y1 - 2005/5

N2 - Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.

AB - Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.

UR - http://www.scopus.com/inward/record.url?scp=27144485326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144485326&partnerID=8YFLogxK

U2 - 10.1016/j.it.2005.03.006

DO - 10.1016/j.it.2005.03.006

M3 - Article

C2 - 15866241

AN - SCOPUS:27144485326

VL - 26

SP - 275

EP - 281

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 5

ER -